BioAtla, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving BioAtla, Inc. now
Current reporting with the operating signal separated from the noise.
BioAtla, Inc.: BioAtla Announces Share Consolidation
Investors are testing whether BioAtla, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.BioAtla, Inc.: BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
The story matters when it changes BioAtla, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript
Investors are testing whether BioAtla, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.BioAtla, Inc. to Present Phase 2 Trial Results of Ozuriftamab Vedotin at ASCO 2025 Annual Meeting
The story matters when it changes BioAtla, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points
The story matters when it changes BioAtla, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.BioAtla, Inc. (NASDAQ:BCAB) has caught the attention of institutional investors who hold a sizeable 39% stake
The story matters when it changes BioAtla, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.BioAtla, Inc. (BCAB) Q3 2023 Earnings Call Transcript
Investors are testing whether BioAtla, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.With 51% ownership of the shares, BioAtla, Inc. (NASDAQ:BCAB) is heavily dominated by institutional owners
Investors are testing whether BioAtla, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Recent uptick might appease BioAtla, Inc. (NASDAQ:BCAB) institutional owners after losing 56% over the past year
The story matters when it changes BioAtla, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.BioAtla, Inc. Common Stock (BCAB)
Investors are testing whether BioAtla, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest BCAB filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
BioAtla, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
SEARCH Q2 COVERAGE →Third quarter
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →